메뉴 건너뛰기




Volumn 48, Issue 6, 2013, Pages 875-877

Dasatinib medication causing profound immunosuppression in a patient after haploidentical SCT: Functional assays from whole blood as diagnostic clues

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYTARABINE; DASATINIB; DAUNORUBICIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; RITUXIMAB; THIOTEPA;

EID: 84879099890     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.246     Document Type: Letter
Times cited : (12)

References (12)
  • 1
    • 33947280081 scopus 로고    scopus 로고
    • Dasatinib induces notable hematologic and cytogenetic responses in chronicphase chronic myeloid leukemia after failure of imatinib therapy
    • Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ et al. Dasatinib induces notable hematologic and cytogenetic responses in chronicphase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109: 2303-2309.
    • (2007) Blood , vol.109 , pp. 2303-2309
    • Hochhaus, A.1    Kantarjian, H.M.2    Baccarani, M.3    Lipton, J.H.4    Apperley, J.F.5    Druker, B.J.6
  • 2
    • 77953725855 scopus 로고    scopus 로고
    • Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
    • Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260-2270.
    • (2010) N Engl J Med , vol.362 , pp. 2260-2270
    • Kantarjian, H.1    Shah, N.P.2    Hochhaus, A.3    Cortes, J.4    Shah, S.5    Ayala, M.6
  • 3
    • 70449467570 scopus 로고    scopus 로고
    • Immunosuppression and atypical infections in CML patients treated with dasatinib at 140mg daily
    • Sillaber C, Herrmann H, Bennett K, Rix U, Baumgartner C, Bohm A et al. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140mg daily. Eur J Clin Invest 2009; 39: 1098-1109.
    • (2009) Eur J Clin Invest , vol.39 , pp. 1098-1109
    • Sillaber, C.1    Herrmann, H.2    Bennett, K.3    Rix, U.4    Baumgartner, C.5    Bohm, A.6
  • 4
    • 45449102076 scopus 로고    scopus 로고
    • The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro
    • Blake S, Hughes TP, Mayrhofer G, Lyons AB. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin Immunol 2008; 127: 330-339.
    • (2008) Clin Immunol , vol.127 , pp. 330-339
    • Blake, S.1    Hughes, T.P.2    Mayrhofer, G.3    Lyons, A.B.4
  • 5
    • 52049085750 scopus 로고    scopus 로고
    • Dasatinib exerts an immunosuppressive effect on CD8\+ T cells specific for viral and leukemia antigens
    • Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Greiner J et al. Dasatinib exerts an immunosuppressive effect on CD8\+ T cells specific for viral and leukemia antigens. Exp Hematol 2008; 36: 1297-1308.
    • (2008) Exp Hematol , vol.36 , pp. 1297-1308
    • Fei, F.1    Yu, Y.2    Schmitt, A.3    Rojewski, M.T.4    Chen, B.5    Greiner, J.6
  • 6
    • 58149181387 scopus 로고    scopus 로고
    • Dasatinib inhibits recombinant viral antigen-specific murine CD4\+ and CD8\+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo
    • Fraser CK, Blake SJ, Diener KR, Lyons AB, Brown MP, Hughes TP et al. Dasatinib inhibits recombinant viral antigen-specific murine CD4\+ and CD8\+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Exp Hematol 2009; 37: 256-265.
    • (2009) Exp Hematol , vol.37 , pp. 256-265
    • Fraser, C.K.1    Blake, S.J.2    Diener, K.R.3    Lyons, A.B.4    Brown, M.P.5    Hughes, T.P.6
  • 8
    • 38949210227 scopus 로고    scopus 로고
    • Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation
    • Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008; 111: 1366-1377.
    • (2008) Blood , vol.111 , pp. 1366-1377
    • Schade, A.E.1    Schieven, G.L.2    Townsend, R.3    Jankowska, A.M.4    Susulic, V.5    Zhang, R.6
  • 10
    • 34247470836 scopus 로고    scopus 로고
    • Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia
    • Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007; 7: 345-356.
    • (2007) Nat Rev Cancer , vol.7 , pp. 345-356
    • Weisberg, E.1    Manley, P.W.2    Cowan-Jacob, S.W.3    Hochhaus, A.4    Griffin, J.D.5
  • 11
    • 77958553932 scopus 로고    scopus 로고
    • Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy
    • Rohon P, Porkka K, Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol 2010; 85: 387-398.
    • (2010) Eur J Haematol , vol.85 , pp. 387-398
    • Rohon, P.1    Porkka, K.2    Mustjoki, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.